AtriCure (NASDAQ:ATRC) Insider Sells 9,370 Shares of Stock

AtriCure, Inc. (NASDAQ:ATRC) insider Karl Dahlquist sold 9,370 shares of the stock in a transaction on Monday, August 24th. The shares were sold at an average price of $48.89, for a total value of $458,099.30. Following the sale, the insider owned 87,319 shares in the company, valued at approximately $4,269,025.91. This trade represents a 9.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

AtriCure Stock Performance

AtriCure stock opened at $48.68 on Wednesday. AtriCure, Inc. has a fifty-two week low of $25.36 and a fifty-two week high of $49.88. The company has a market capitalization of $2.48 billion, a price-to-earnings ratio of 231.82 and a beta of 1.20. The stock has a fifty day moving average of $36.67 and a two-hundred day moving average of $31.97. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The business had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period in the prior year, the business earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, analysts anticipate that AtriCure, Inc. will post 0.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Geneos Wealth Management Inc. purchased a new position in shares of AtriCure during the 2nd quarter worth about $37,000. Harbor Investment Advisory LLC purchased a new stake in AtriCure in the second quarter valued at approximately $40,000. Allworth Financial LP purchased a new stake in AtriCure in the second quarter valued at approximately $43,000. Smartleaf Asset Management LLC increased its holdings in shares of AtriCure by 59.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after buying an additional 429 shares during the last quarter. Finally, Fifth Third Bancorp acquired a new stake in AtriCure during the first quarter worth about $51,000. Institutional investors and hedge funds own 99.11% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Citigroup restated a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. Zacks Research downgraded shares of AtriCure from a “strong-buy” rating to a “hold” rating in a report on Monday. Canaccord Genuity Group boosted their price objective on shares of AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. BTIG Research upped their price objective on shares of AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Monday. Finally, Raymond James Financial set a $52.00 target price on shares of AtriCure in a research report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $48.62.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.